AP -- Regulators are exploring whether organ transplant drugs made by Roche and Novartis increase the risk of an often-fatal neurological disease. The Food and Drug Administration said Thursday it has identified 16 cases of patients developing the rare neurological ailment while taking Roche’s drug CellCept, which is used to avoid rejection in organ transplant patients. U.S. regulators approved CellCept in 1995.
